Effect of the PGD$_2$-DP signaling pathway on primary cultured rat hippocampal neuron injury caused by aluminum overload

Jie Ma*, Qunfang Yang*, Yuling Wei, Yang Yang, Chaonan Ji, Xinyue Hu, Shaoshan Mai, Shengnan Kuang, Xiaoyan Tian, Ying Luo, Guojuan Liang & Junqing Yang

In the present study, the agonists and antagonists of DP receptor were used to examine whether the PGD$_2$-DP signaling pathway affects neuronal function. Primary cultured hippocampal neuron was prepared and treated with aluminum maltolate (100 μM) to establish the neuronal damage model. PGD$_2$ and cAMP content was detected by ELISA. L-PGDS and DPs mRNA and protein expression were measured by RT-PCR and Western blotting, respectively. The aluminium-load neuron was treated with the DP$_1$ agonist BW245C, the DP$_1$ antagonist BWA868C, the DP$_2$ agonist DK-PGD$_2$, and the DP$_2$ antagonist CAY10471, respectively. Neuronal pathomorphology was observed using H-E staining. The cell viability and the lactate dehydrogenase leakage rates of neurons were measured with MTT and LDH kit, respectively. Ca$_{2+}$ level was detected by Fluo-3/AM. In the model group, the MTT values obviously decreased; LDH leakage rates and PGD$_2$ content increased significantly; L-PGDS, DP$_1$ mRNA and protein expressions increased, and DP$_2$ level decreased. BW245C reduced the Ca$_{2+}$ fluorescence intensity and protected the neurons. DK-PGD$_2$ increased the intensity of Ca$_{2+}$ fluorescence, while CAY10471 had the opposite effect. In conclusion, contrary to the effect of DP$_2$, the PGD$_2$-DP$_1$ signaling pathway protects against the primary cultured rat hippocampal neuronal injury caused by aluminum overload.

Neurodegenerative diseases (NDDs) of the central nervous system (CNS), including Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD), have increased dramatically in recent years, comprising 30% of the total cases of disease in humans. Though the current medical treatments have significantly improved the quality and length of life for NDD patients, NDDs remain a significant unresolved societal burden that afflicts millions of people worldwide.

Many studies have shown that the pathogenesis of the NDDs includes ischemia, calcium overload, oxidative stress and inflammatory factors$^{1-6}$. Among these factors, neuronal damage and apoptosis caused by inflammatory cytokines have been widely recognized.

Aluminum (Al), which is abundant in the crust, is omnipresent in everyday life and may enter the human body in many ways such as the environment, diet, or drugs. However, the physiological action of Al on humans is unclear. Since the first report of Al toxicity to humans at early 1970s, it has been identified that Al overload could cause severe brain damage and neurodegeneration$^7$. In particular, Al was detected in senile plaques and neurofibrillary tangles in the brain tissues from AD patients$^8$. Therefore, Al neurotoxicity could be involved in the degeneration of neurons and the production of Aβ peptide. As reported, the Al-induced neuronal injury is closely related to neuroinflammatory.

Inflammation is partially mediated by prostaglandins, which are mediated by the rate-limiting enzyme cyclooxygenase (COX). To date, studies on the significance of COX-2 and its metabolites in neural degenerative diseases suggest that Alzheimer’s disease is associated with the over-expression of COX-2$^{9-11}$. Thus, COX-2 inhibitors have been widely used. Unfortunately, COX-2 inhibitors cause many side effects, such as renal toxicity$^{12}$.
decreased ulcer healing\textsuperscript{13} and adverse cardiovascular reactions\textsuperscript{14}. To avoid such side effects, it is a key to determine the significance of the COX-2 downstream signaling pathway in nerve injury.

Prostaglandins (PGs) are a type of unsaturated fatty acid derivative produced from arachidonic acid catalyzed by COX\textsuperscript{15}. Prostaglandin D\textsubscript{1} is one of the most abundant PGs synthesized by PGDS in the brain\textsuperscript{16}. PGDS includes L-PGDS (lipocalintype prostaglandin D synthase) and H-PGDS (hematopoietic prostaglandin D synthase). L-PGDS is highly expressed in the central nervous system\textsuperscript{17}. Several studies have suggested that PGD\textsubscript{1} may protect against neuronal lesions caused by multiple factors\textsuperscript{18}; but it has also been reported that PGD\textsubscript{2} can cause hippocampal neuron apoptosis\textsuperscript{19,20}. PGD\textsubscript{2} plays a role via activating on prostaglandin D\textsubscript{1} and prostaglandin D\textsubscript{2} receptors. Focusing on the PGD\textsubscript{2}-DP signaling pathway, this study aimed to evaluate the characteristics and significance of the changes of DP\textsubscript{1} and DP\textsubscript{2} in primary cultured hippocampal neuron treated with aluminum overload.

This experiment established the injury model of rat hippocampal neurons induced by aluminum overload in vitro and evaluated the characteristics of the PGDS-DP pathway by the methods of ELISA, PCR, Western blotting etc. Additionally, neurons were treated with the DP\textsubscript{1} agonist BW245C, the DP\textsubscript{1} antagonist BWA868C, the DP\textsubscript{2} agonist DK-PGD\textsubscript{2} and the DP\textsubscript{2} antagonist CAY10471 to investigate the characteristics and significance of the changes of the PGDS-DP pathway. The results of our present study will provide a powerful experimental and theoretical basis for further research on the mechanism of the neuronal injury induced by aluminum overload, facilitating the development of drugs for the effective treatment of NND\textsubscript{3}.

**Results**

**Primary cultured and identification of neurons.** Observed under inverted microscope, the neuronal soma was plumped with short processes after cultured 1 day. The neurons appeared oval or vertebral after 3 days, and they had become stereoscopic. For 7 days, the cultured neuronal bodies enlarged and the nervous process eruption and extension into reticulation. The purity of the hippocampus neurons was detected by neuron specific enolase (NSE) after cultured for 7 d. The bodies and axons of the positive cells were stained to be brown by NSE and nuclei were stained to be blue after counterstained with hematoxylin. One hundred cells were selected randomly to evaluate the number and the percentage of positive cells. Our results showed that there were more than 95% of positive cells (Fig. 1).

**Dose-dependent effect of Al (malt)\textsubscript{3} and maltol on neuronal viability.** The results showed that compared with the control group, the neuron viability decreased significantly in the Al\textsuperscript{3+}-treated group at the concentration of 100, 200 and 400 μM with the neuron survival rates of 69.17%, 39.97% and 27.66%, respectively. However, the neuron survival rate was 95.47% at the concentration of 50 μM of Al (malt), which was no substantial difference compared with the control group. There was no considerable difference between the control group and the solvent control (maltol) (100–1200 μM) group. Considering each ion of Al is bound to three molecules of maltolate, 100 μM of Al (malt)\textsubscript{3} and 300 μM of maltol were used in following experiments to evaluate the effects of PGD\textsubscript{2}-DP signaling on Al-load neuron (Fig. 2).

**Expression of DP\textsubscript{1}, DP\textsubscript{2} and L-PGDS mRNAs and proteins in primary cultured rat hippocampal neurons.** Compared with control group, the expression of L-PGDS and DP1 mRNA up-regulated 100% in the
model group which was treated with Al (malt)₃ (P < 0.01). By contrast, the expression of DP₂ mRNA decreased significantly more than 70% in the model group (P < 0.01) (Fig. 3A).

The results of WB showed that compared with control group, the expression of L-PGDS proteins increased 50% (P < 0.01), and that of DP₁ proteins nearly doubled in the Al³⁺-treated group (P < 0.05), however the expression of the DP₂ proteins decreased 50% in the Al³⁺-treated group (P < 0.05) (Fig. 3B).

**The content of PGD₂ was detected by Enzyme-linked Immunosorbent Assay.** In control group, the concentration of PGD₂ was about 4pg/mg whereas it was approximately 50 pg/mg in Al³⁺-treated group which showed nearly 12 times of that in the control group. Compared with the control group, the content of PGD₂ increased significantly in model group (P < 0.01) (Fig. 4).

**The change of neuron viability intervened by the DP agonists and antagonists.** About the concentrations of the agonists and antagonists of DP, for the observation of neuronal viability, seven concentrations (10⁻³, 3 × 10⁻³, 10⁻⁴, 3 × 10⁻⁴, 10⁻⁵, 3 × 10⁻⁵, 10⁻⁶, 3 × 10⁻⁶ M) of each agonist and antagonist of DP were used. The results showed that compared with the control group, the neuron viability decreased significantly in model group (P < 0.01) and that treatment of DP₂ agonists (BW245C) at a concentration of 10⁻⁵, 3 × 10⁻⁵ and 10⁻⁶ M increased significantly the neuron viability compared with model group, whereas the viability of neuron treated with DP₁ antagonist (BWA868C) of 10⁻⁵ M was decreased significantly (P < 0.01). Compared with model group, the neuron viability in the DP₂ antagonist (CAY10471) (10⁻⁶, 3 × 10⁻⁶ and 10⁻⁷ M) -treated group was increased substantially. The administration of DP₂ agonists (DK-PGD₂) at a concentration of 10⁻⁵ and 3 × 10⁻⁵ M decreased neuron viability significantly (P < 0.01). There was no considerable difference between the control group and the solvent control group (Fig. 5).

We found each agonist and antagonist of DP had significant effects on neuron viability at a concentration of 10⁻⁶, 3 × 10⁻⁶ and 10⁻⁵ M, so we used the three concentrations of 10⁻⁶, 3 × 10⁻⁶ and 10⁻⁵ M of each agonist and antagonist of DP in lactate dehydrogenase leakage rate test.

**The change of LDH leakage rate intervened with the DP agonists and antagonists.** Compared with the control group, the solvent control group of primary cultured hippocampal neurons exhibited no considerable change in the LDH leakage rate, while the rate of LDH leakage rose significantly in the Al³⁺-treated group (P < 0.01). The DP₁ agonist (BW245C) blunted the increase of leakage rate of LDH in Al (malt)₃ -treated group in a concentration dependent manner (P < 0.01). The DP₁ antagonist (BWA868C) of 10⁻⁵ M increased significantly the LDH leakage rate in Al (malt)₃ -treated group (P < 0.01). The LDH leakage rate was increased significantly when treated with the DP₂ agonists (DK-PGD₂) at concentration of 10⁻⁵ M and 3 × 10⁻⁵ M (P < 0.01). The LDH leakage rate reduced significantly when treated with the DP₂ antagonist (CAY10471) at different concentrations (10⁻⁵, 3 × 10⁻⁵ and 10⁻⁴ M) (P < 0.01) (Fig. 6).

Considering that there were a dose-dependent effect of each agonist and antagonist of DP at concentration of 10⁻⁵, 3 × 10⁻⁵ and 10⁻⁴ M on neuron viability and LDH leakage by Al, so, only the 10⁻⁵ M of the agonists and antagonists of DP were used in the observation of change of the neuronal pathology, cAMP content and Ca²⁺ fluorescence intensity in Al³⁺-treated neurons.

**The pathological change of primary cultured rat hippocampal neurons intervened with the DP agonists and antagonists.** The structures of primary cultured hippocampal neurons were clear, complete and the protrusions of neurons were interwoven into the meshes in the control group. Compared with the control
Figure 3. Levels of DP₁, DP₂ and L-PGDS in primary cultured rat hippocampal neurons detected by reverse transcription polymerase chain reaction. (A) The expressions of L-PGDS, DP₃ mRNA were measured by RT-PCR. The relative mRNA level of L-PGDS, DP₁ levels and decrease of DP₂ level compared with the control group. (B) The expressions of L-PGDS, DP₁ proteins were measured by WB. The relative protein levels of L-PGDS, DP₁, DP₂ proteins were standardized to endogenous β-actin protein for each sample. Al₃⁺ administration caused the significant increase of L-PGDS, DP₁ levels and decrease of DP₂ level compared with the control group. Values were mean ±SD (n = 3, **P < 0.01 vs. control group, one-way ANOVA with Dunnett's multiple comparisons).

Figure 4. The content of PGD₂ in each group detected by ELISA. The content of PGD₂ raised significantly in the Al₃⁺-treated group. Values were mean ± SD (n = 6, **P < 0.01 vs. control group, Student's t test).
group, the number of neurons was substantially decreased and the protrusions were degenerated in the Al\(^{3+}\)-treated group. Compared with the Al\(^{3+}\)-treated group, the number of neurons increased and the structures recovered in BW245C-treated group. Treated with BW A868C, the neuronal injury was further aggravated compared with the Al\(^{3+}\)-treated group. Treated with DK-PGD2, the hippocampal neurons almost exhibited karyopyknosis and disruption, whereas the bodies and nucleus of neurons were still clear and karyopyknosis compared with the Al\(^{3+}\)-treated group. The neuronal injury in the Al\(^{3+}\)-treated group was considerably reduced when treated with CAY10471 (Fig. 7A).

The content of cAMP was detected by Enzyme-linked Immunosorbent Assay. The content of cAMP reduced significantly in the Al\(^{3+}\)-treated group. Compared with the Al\(^{3+}\)-treated group, the content of cAMP increased significantly when DP1 was activated or DP2 was inhibited (P < 0.05), whereas the content of cAMP showed a trend of decrease when DP1 was inhibited and the content of cAMP decreased significantly when DP2 was activated (P < 0.05) (Fig. 7B).

Effect of DP interventions on the Ca\(^{2+}\) fluorescence intensity of primary cultured rat hippocampal neurons. The intensity of Ca\(^{2+}\) fluorescence was very weak in the control group. However, the intensity of Ca\(^{2+}\) fluorescence was significantly increased in the Al\(^{3+}\)-treated group compared with the control group (P < 0.01) (Fig. 7C). Compared with the Al\(^{3+}\)-treated group, the Ca\(^{2+}\) fluorescence intensity was reduced significantly by treatment of BW245C (P < 0.01). Treated with BWA868C or DK-PGD2, the intensity of Ca\(^{2+}\) fluorescence slightly increased in primary cultured hippocampal neurons. In contrast, compared with the Al\(^{3+}\)-treated group, treatment of CAY10471 decreased significantly the intensity of Ca\(^{2+}\) fluorescence (P < 0.01) (Fig. 7D).

Discussion
Aluminum accumulation may cause damage to cognitive function and central nervous system\(^2\). Maltol is a by-product of the hydrolysis of starch or sucrose, and it is also a common food additive\(^2\). Al (malt)\(_3\) can release...
Al(III) under physiological pH conditions eg in the gastrointestinal acid environment and facilitate the neurotoxicity23. Johnson et al. found that Al (malt)3 can cause apoptosis in primary cultured rat hippocampal neurons with time- and dose-dependent22. Our experiments showed that compared with the control group, MTT values were significantly decreased after treated with 100 μM Al (malt)3 for 24 hours in primary hippocampal neurons, while the LDH leakage rates were increased significantly. These results indicated that the injury model was successful.

COX and PGDS are the important rate-limiting enzymes for the synthesis of PGH2. PGDS has two subtypes, H-PGDS and L-PGDS. H-PGDS is mainly expressed in the placenta, lung, brain, and other tissues19,24. L-PGDS is the only trace protein in the lipocalin super family, which is mainly distributed in the brain and the reproductive organs and secreted into the cerebrospinal fluid, plasma and seminal fluid25,26. In recent years, it has been found that the expression of L-PGDS is related to cell apoptosis in the central nervous system27,28. The results of the present study showed that the expressions of L-PGDS mRNA and protein in the injury model induced by Al (malt)3 were significantly increased, suggested that L-PGDS may be involved in neuronal degeneration.

PGD2 is widely distributed and synthesized in the peripheral and central nervous systems. In the periphery, the main physiological functions of PGD2 contain the regulation of vascular diastolic and systolic pressure, and the inhibition of platelet aggregation29–31. In the brain, the main physiological functions of PGD2 contain the regulation of sleep, body temperature, olfactory function, sexual hormones and anti-anxiety effects32. In addition, PGD2 can significantly increase the contents of NGF (neuron growth factor) and BDNF (brain-derived neurotrophic factor), indicating that PGD2 may play a neuroprotective role in the CNS30. Our experimental results in this study showed that the PGD2 level increased significantly in the primary cultured rat hippocampal neurons, the main cause may be the intracellular calcium overload which sets free radicals to activate phospholipase A2 (PLA2) which can produce more AA when Al is accumulated. At the same time, the expression of L-PGDS increased, and then the synthesis of PGD2 increased.

PGD2 acts as a potent positive modulator of DP receptors. There are two receptor subtypes for PGD2, DP1 receptor and DP2 receptor. DP1 is characterized by low expression, and it is mainly expressed in the hippocampus, cortex, hypothalamus and striatum of the brain tissue in addition to the peripheral circulation. Studies indicated that compared with the C57 mice, the susceptibility of C57 DP1 (−/−) mice to ischemia reperfusion injury was enhanced and the infarction area was significantly amplified33, suggesting that DP1 plays an obvious protective role in the ischemia reperfusion injury of brain. However, the protective mechanisms still unknown. DP3 is characterized by low expression, either, and it is widely distributed in the thalamus, cortex, hippocampus and other parts of the CNS. Studies reported that DP3 showed high expression and an excitotoxicity in normal hippocampal

![Figure 6. The change of LDH leakage rate intervened with the DP agonists and antagonists. (a) BW245C and (d) CAY10471 significantly decreased the LDH leakage rate in Al(III)-treated groups. (b) BWA868C and (c) DK-PGD2 increased the LDH leakage rate in Al(III)-treated groups. Values were mean ± SD of four individual experiments (n = 4. **P < 0.01 compared with control group. ***P < 0.01 compared with Al(III)-treated group, one-way ANOVA with Dunnett’s multiple comparisons).](image)
pyramidal neurons, and that DP1 agonist could significantly enhance the damage of the hippocampal CA1 and CA3 neurons caused by glutamate toxicity. In general, DP1 plays a protective role in the excitotoxicity and ischemic brain injury model, while DP2 accelerates the process of brain injury.

In our study, we found that the content of PGD2 significantly increased after treated with aluminum in primary cultured rat hippocampal neurons as well as the expression of L-PGDS and DP1, whereas the expression of DP2 decreased. The results suggested that the PGD2-DP pathway may be involved in the injury of neurons. When DP1 was stimulated, the content of cAMP in the neurons and the release of Ca2+ increased, the barrier function of endothelial neurons enhanced. However, research indicated that PGD2 promoted the aggregation of astrocytes in epileptic mice by activating DP1. Liang et al. reported that BW245C can significantly reduce the mortality of neurons caused by the treatment of primary hippocampal neurons and hippocampal slices with NMDA. Ahmad et al. found that BW245C can significantly reduce the brain damage and magnified the cerebral infarction area caused by NMDA. Saleem et al. found that the viability of primary cultured mouse cortical neurons damage induced by glutamate was improved after treated with BW245C, whereas the viability of neurons showed non-significant changes after treated with BW A868C. However, these results indicated that the specific effects of DP1 and DP2 on neuronal damage are still unclear. Therefore, in our experiment, we intervened in the PGD2-DP pathway with DP agonists and antagonists to clarify the importance of this pathway in the injury progress of primary cultured rat hippocampal neurons induced by aluminum. In our study, compared with the Al (malt)3 treated groups, the number of hippocampal neurons significantly increased after treated with DP1 agonist (BW245C). At the same time, protrusions were interwoven into the mesh and the MTT values increased greatly. In addition, the LDH leakage rate and the intensity of Ca2+ fluorescence decreased significantly. In the DP1 antagonist (BW A868C)-treated group, hippocampal neuronal bodies ruptured and neuronal viability decreased.

Figure 7. The effects of the DP agonists and antagonists on primary cultured rat hippocampal neurons. (A) The picture showed the number and structure of neurons in (a) control group and (b) Al3+-treated group. (c) BW245C- treated group and (f) CAY10471-treated group raised the number and structure of neurons in model group, whereas (d) BWA868C-treated group and (e) DK-PGD2- treated group decreased the number and structure of neurons in the Al3+-treated group. Sections were pictured at × 400. (B) The intervention effect of DP on the cAMP level in the Al3+-treated group. Values were mean ± SD of six individual experiments. (n = 6, **P < 0.01 vs. control group. *P < 0.05 vs. Al-treated group, one-way ANOVA with Dunnett's multiple comparisons) (C) The picture showed the Ca2+ fluorescence of neurons in (a) control group and (b) model group, (c) BW245C and (f) CAY10471 decreased the Ca2+ fluorescence of neurons in model group. (d) BWA868C and (e) DK-PGD2 increased the Ca2+ fluorescence compared with model group (×400). (D) Summary graph showed the intensity of Ca2+ fluorescence relative levels in DP agonists and antagonists groups against model group. Values were mean ± SD of ten individual experiments (n = 10. **P < 0.01 compared with control group. **P < 0.01 compared with Al3+-treated group, one-way ANOVA with Dunnett’s multiple comparisons).
structures were incomplete, meanwhile MTT values reduced and the LDH leakage rate increased significantly although the changes of the intensity of Ca$^{2+}$ fluorescence were not obvious in the BWA868C-treated group. Our experimental results are consistent with that of the study of Saleem et al. Moreover, it was proved that the survival rates of neurons can be increased by BW245C, while the opposite results were observed by BWA868C, suggesting that the expression and activation of DP2 could reduce the injury susceptibility of hippocampal neurons to aluminum toxicity.

Studies also reported that DP2 receptors were activated coupled to Gi protein and inhibited CAMP levels, increasing Ca$^{2+}$ in neurons. In our experiments, we found that all of the neurons in the DK-PGD2 (DP2 agonist)-treated group underwent death compared with model group. These data also showed that MTT value decreased, LDH leakage rate increased significantly and the intensity of Ca$^{2+}$ fluorescence rose up. Karyopyknosis and disruption of neurons significantly reduced in the CAY10471 (DP2 antagonist) -treated group, while MTT values increased, and LDH leakage rates reduced. These results in the present study suggested that DP2 may mediate the neurotoxicity of PGD2.

However, it has also been reported that the DP2 antagonist BAY-u3405 does not affect on the injury model induced by PGD2, and it is speculated that DP2 may not mediate the neurotoxicity of PGD2. The contradictory effects of DP2 on neurons may be related to the neuron type and the degree of damage, and it needs further research in order to clarify its effect on neurons apoptosis in the over-expression DP2, or knockout mice. However, in this experiment, DK-PGD2 decreased the survival rates of neurons by activating DP2, whereas CAY10471 increased the survival rates by antagonizing DP2, indicating that the susceptibility of hippocampal neurons to aluminum neurotoxicity is increased by activating and expressing of DP2. This mechanism may be involved that its effect on DP receptor by regulating the Ca$^{2+}$ signaling pathway, but the specific mechanism of the neural system is still unclear.

In conclusion, the expression of DP2 increased while DP1 decreased in the model induced by aluminum. DP1 expression and activation could decrease the injury susceptibility of hippocampal neurons to aluminum toxicity. The susceptibility of hippocampal neurons to aluminum neurotoxicity increased by activating and expressing of DP2. These results suggested that DP2 may protect the primary cultured hippocampal neuron from aluminum load damage, whereas DP1 may be harmful. DP can be considered as a potential candidate target for treatment of brain injury and neurodegenerative disease. However, considering the complex COX-2 downstream pathway, the complex regulation mechanism of DP in the central nervous system is worth our further study.

Methods

Animals. Rats were housed in the barrier housing facility, and it has in keeping with national standard “Laboratory Animal—Requirements of Environment and Housing Facilities”. The care of laboratory animal and the animal experimental operation have conforming to “Chongqing Administration Rule of Laboratory Animal”. The experimental procedures were approved by the animal laboratory administrative center and the institutional ethics committee of Chongqing Medical University (License number: SYXK YU 2012-0001) and also in accordance with the National Institutes of Health guidelines.

Chemicals. AlCl$_3$·6H$_2$O (Sinopharm Chemical Reagent Co., Ltd., China) and maltol (Aladdin, USA) were of analytical grade. Aluminum maltol solution (20 mM) was prepared by adding 1.513 g maltol and 0.483 g of AlCl$_3$·6H$_2$O into 200 ml of autoclaved PBS. The 20 mM maltol aluminum was stored at 4 °C until used with the methods. BW245C and CAY1047 (Cayman, USA) were dissolved in the DMSO (Sigma, USA) to be 10 mM reserve liquid. BWA868C and DK-PGD2 (Cayman, USA) were dissolved in methyl acetate to be 3.5 mM reserve liquid.

Rat primary hippocampal neuron culture. Primary hippocampal neurons were prepared from E18 rat embryos and were immediately soaked with 75% ethanol. The hippocampus was isolated from the brain of each rat and the tissues were minced with 0.125% trypsin at 37 °C for 20 min; digestion was stopped with the addition of 10% fetal bovine serum (FBS) (Gibco, USA). The neurons were centrifuged and suspended to a density of $1 \times 10^5$ /L in DMEM (HyClone, USA) with 10% FBS in it. The different volumes of neuronal suspensions were inoculated in culture flasks and coated with L-poly lysine (Sigma, USA) and cultured in a humidified 5% CO$_2$ atmosphere at 37°C. When the neurons adhered, the medium was changed to neurobasal medium (Gibco, USA).

Neuron-specific enolase identification. Hippocampal neurons grown on glass cover slips were rinsed three times with PBS and fixed with 4% paraformaldehyde for 30 min at 4 °C and for 10 min at room temperature. The activity of endogenous peroxidase in the neurons was quenched with 3% H$_2$O$_2$ for 15 min. Goat serum (10%) was used as a blocking solution for 20 min at room temperature after three times washing. Then, neurons were incubated overnight at 4°C with the appropriate dilutions of antibodies (NSE 1:50) (Boston, China). Afterward, the neurons were incubated with the secondary antibody (biotin-labeled goat anti-rabbit) for 30 min at 37 °C and with horseradish peroxidase-labeled avidin at 37 °C for 30 min. DAB (ZSGB, China) was used to analyze color development, and the samples were counterstained with hematoxylin, dehydrated with a series of graded alcohols, treated with xylene and sealed with neutral gum.

Establishment of models. On the seventh day, hippocampal neurons were divided into the control group, four solvent groups and four Al$^{3+}$-treated groups. PBS was added into the control group, 100, 300, 600, 1200 μM of maltol was added into the solvent group, respectively. While 50, 100, 200 and 400 μM Al (malt)$_3$ were added into the model group, respectively. After the experiment, the most suitable concentration of Al (malt)$_3$ was selected in following experiments.

PGD$_2$ was detected by Enzyme-Linked Immunosorbent Assay (ELISA). The rat hippocampal neurons were cultured in the flasks and divided into the control group and the Al$^{3+}$-treated group until D7. After 24 h,
neurons were collected after trypsin digestion. The levels of PGD₂ were detected by ELISA kits (Cloud-Clone Corp, USA), following the manufacturer's protocols.

Reverse Transcription Polymerase Chain Reaction (RT-PCR). To determine the expressions of L-PGDS, DP₁, and DP₂ mRNA in the control and the model groups, total RNA was extracted from the neurons using RNAiso Plus reagent (Takara, China) to generate cDNA templates by reverse transcription (RT) kit (Takara, China) following the manufacturer's instructions, and then amplified by using the MIX PCR kit (Cwbio, China). PCR products were separated by 2% agarose gel electrophoresis and visualized by ethidium bromide staining. All the samples were normalized by the expression level of β-actin. The absorbance values of L-PGDS, DP₁, and DP₂ mRNA were measured with a Bio-Rad gel imaging analysis system (Bio-Rad, USA). The primer sequences for L-PGDS were: forward 5′-ATGTTGCAAGACGTGAGC-3′ and reverse 5′-TGGTCCCTTGCTAAAAGTGATG-3′ (410 bp), DP₁ (5′-TGAACTGTCCTACTGCCTTG-3′ and 5′-GGTTGATGGCCTTTGTGTAAGA-3′, 320 bp), DP₂ (5′-CTTCCAAACACACAGCAACTC-3′ and 5′-CAGAGGATCGGCAGGACTC-3′, 326 bp), β-actin (5′-AAGTCCAGTATCACTATCG-3′ and 5′-GG CATAGAGGTCTTTACGGATG-3′, 155 bp).

Western blotting. Neurons from each group were homogenized within 10 volumes of ice-cold homogenization buffer and centrifuged at 12,000 × g for 10 min at 4°C. The supernatant was collected, and the protein concentrations were determined with a BCA protein assay kit (Beyotime, China). Twenty micrograms of protein was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to PVDF membranes (Millipore, USA). The membranes were blocked with 5% non-fat dry milk for 1 h at room temperature and then probed with specific primary antibodies, including anti-L-PGDS, DP₁, DP₂ (1:100; Cayman, USA), and β-actin (1:1000; Boston, China) overnight at 4°C. The membranes were washed for three times in TBST and incubated with HRP-conjugated secondary antibodies at room temperature for 1 h, and then washed four times in TBST; protein signals were visualized by ECL (Bio-Rad, USA). Quantification of data and subsequent statistical analyses were performed with Image Lab.

Detection of neuron viability. The primary cultured hippocampal neuronal viability was determined by 3-(4,5-Dimethyl-thiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) (Sigma, USA) assay. The neurons were plated in 96-well culture plates at a density of 1 × 10⁵ neurons/ml. The neurons were divided into the control group, the solvent control group, the Al³⁺-treated group and the intervention group. Different drugs including DP₁ agonist (BW245C), DP₂, antagonist (BWA868C), DP₂, agonist (DK-PGD₂), and DP₂, antagonist (CAY10471) were added up into the intervention group respectively with various concentrations (10⁻³, 3 × 10⁻⁵, 10⁻⁶, 3 × 10⁻⁶, 10⁻⁷, 3 × 10⁻⁷, 10⁻⁸, 3 × 10⁻⁸ M) for 24 hours at 37 °C and 5% CO₂. Then, the supernatant was discarded and 100 µl of 5 mg/ml MTT was added to each well. The media was carefully removed and the color was developed after incubation with 150 µl DMSO for 4 hours. Finally, absorbance (OD) was read at 570 nm by a micro plate reader (BioTek, USA). The cultured rat hippocampal neurons in the 24-well culture plate were cultured until D7 for drug treatment. The neurons were divided into the control group, the solvent control group, the Al³⁺-treated group and the intervention group. Different drugs including DP₁, agonist (BW245C), DP₂, antagonist (BWA868C), DP₂, agonist (DK-PGD₂), and DP₂, antagonist (CAY10471) were added up into the intervention group respectively with various concentrations (10⁻³, 3 × 10⁻⁵, 10⁻⁶ M) for 24 hours at 37 °C and 5% CO₂. Then, the LDH test kit was used according to the manufacturer’s instructions (Beyotime, China).

Lactate dehydrogenase (LDH) leakage rate measure. The cultured rat hippocampal neurons in the 24-well culture plate were cultured until D7 for drug treatment. The neurons were divided into the control group, the solvent control group, the Al³⁺-treated group and the intervention group. Different drugs including DP₁, agonist (BW245C), DP₂, antagonist (BWA868C), DP₂, agonist (DK-PGD₂), and DP₂, antagonist (CAY10471) were added up into the intervention group respectively with various concentrations (10⁻³, 3 × 10⁻⁵, 10⁻⁶ M) for 24 hours at 37 °C and 5% CO₂. Then, the LDH test kit was used according to the manufacturer’s instructions (Beyotime, China).

Observation of pathological morphology. Cover slips (10 mm × 10 mm) were applied to the 24 wells of rat hippocampal neurons from cultured until D7 for drug treatment. The neurons were divided into the control group, the solvent control group, the Al³⁺-treated group and the intervention group. Different drugs including DP₁, agonist (BW245C), DP₂, antagonist (BWA868C), DP₂, agonist (DK-PGD₂), and DP₂, antagonist (CAY10471) were added up into the intervention group respectively with various concentrations (10⁻³, 3 × 10⁻⁵, 10⁻⁶ M) for 24 hours at 37 °C and 5% CO₂. Then, the LDH test kit was used according to the manufacturer’s instructions (Beyotime, China).

Content of cAMP detection by ELISA. The hippocampal neurons were divided into groups: the control group, the normal solvent group (300 µM of maltol), the normal intervention group (10⁻³ M BW245C, BWA868C, DK-PGD₂, and CAY10471) (Cayman, USA), the model group (100 µM Al(malt)₃), the model solvent group (Al(malt)₃ + 10⁻³ M DMSO), and the model intervention group (Al(malt)₃ + 10⁻³ M BW245C, BWA868C, DK-PGD₂, CAY10471).

Concentration of Ca²⁺ detection. The cultured rat hippocampal neurons in the special culture dish were cultured until D7 for drug treatment. The neurons were divided into the control group, the solvent control group, the Al³⁺-treated group and intervention group. Different drugs including DP₁, agonist (BW245C), DP₂, antagonist (BWA868C), DP₂, agonist (DK-PGD₂), and DP₂, antagonist (CAY10471) were added up into the intervention group at the concentration of 10⁻³ M, respectively for 24 hours at 37 °C and 5% CO₂. The culture medium was removed, Fluo-3/AM was labeled with a fluorescent Ca²⁺ probe, the intensity of Ca²⁺ fluorescence was observed and measured with a laser scanning confocal microscope (Bio-Rad, USA). At the same time, 10 cells were randomly selected in the uniformity field of the fluorescence intensity to analyze the fluorescence intensity.
Statistical analysis. Data were presented as mean ± SD. All data were analyzed with SPSS 12.0 (SPSS Inc. Chicago, US) unless otherwise indicated. For the content of PGD₂, statistical significance was determined by Student’s t test for pairwise comparisons. For RT-PCR, WB, LDH and MTT data, statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons. p < 0.05 was considered statistically significant.

References
1. Amantea, D., Nappi, G., Bernardi, G., Bagetta, G. & Corasaniti, M. T. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBs J. 276, 13–26 (2009).
2. Chan, P. H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 21, 2–14 (2001).
3. Fekeete, A., Vai, E. S., Kovacs, K. J., Lendvai, B. & Zelles, T. Layer-specific differences in reactive oxygen species levels after oxygen-glucose deprivation in acute hippocampal slices. Free Radic Biol Med. 44, 1010–1022 (2008).
4. Kiewert, C. et al. Role of glycine receptors and glycine release for the neuroprotective activity of bilobalide. Brain Res. 1201, 143–150 (2008).
5. Liu, K., Yan, M., Zheng, X. & Yang, Y. The dynamic detection of NO during the ischemic postconditioning against global cerebral ischemia/reperfusion injury. Nitric Oxide. 38, 17–25 (2014).
6. Ortanir, M. N. et al. The beneficial effects of 18β-glycyrrhetinic acid following oxidative and neuronal damage in brain tissue caused by global cerebral ischemia/reperfusion in a C57BL/6J mouse model. Neurosci. 35, 1221–1228 (2014).
7. Frisardi, V. et al. Aluminum in the diet and Alzheimer’s disease: from current epidemiology to possible disease-modifying treatment. J Alzheimers Dis. 20, 17–30 (2010).
8. Shaw, C. A. & Tomijenovice, L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res. 56, 304–316 (2013).
9. Dore, S. et al. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann. Neurol. 54, 155–162 (2003).
10. Int’ Veld, B. A. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 345, 1515–1521 (2001).
11. Yu, L. et al. Time course change of COX2-PGI2/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus. Behav Brain Funct. 10, 42 (2014).
12. Schütz, F. J. Cyclooxygenase-2-specific inhibitors: are they safe? Am J Med. 110, 465–495 (2001).
13. Whittle, B. J. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol. 500, 427–439 (2004).
14. Jaturapatporn, D., Isaac, M. G., McCleery, J. & Tabet, N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev. 2, CD006378 (2012).
15. Hao, C. M. & Breyer, M. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int. 71, 1105–1115 (2007).
16. Narumiya, S., Ogorochi, T., Nakao, K. & Hayashi, O. Prostaglandin D2 in rat brain, spinal cord and pituitary: basal level and regional distribution. Life Sci. 31, 2093–2103 (1982).
17. Medani, M. et al. Prostaglandin D2 regulates human colonic ion transport via the DP1 receptor. Life Sci. 122, 87–91 (2015).
18. Chen, C. P., Chen, R. L. & Preston, J. E. Age-related increase of prostaglandin D2 synthase concentration and glycination in ovine cerebrospinal fluid. Exp Gerontol. 44, 639–645 (2009).
19. Liang, X., Wu, L., Hand, T. & Andreasson, K. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J Neurochem. 92, 477–486 (2005).
20. Rohn, T., Wong, S. M., Cotman, C. W. & Cribbs, D. H. 15-deoxy-delta12,14-prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-gamma, induces neuronal apoptosis. Neuroreport. 12, 839–843 (2001).
21. Molloy, D. W. et al. Effects of acute exposure to aluminum on cognition in humans. J Toxicol Environ Health A. 70, 2011–2019 (2007).
22. Johnson, V. J., Kim, S. H. & Sharma, R. P. Aluminum-maltolate induces apoptosis and necrosis in neuro-2a cells: potential role for p53 signaling. Toxicol Sci. 83, 329–339 (2005).
23. Bharath et al. A new insight on Al-maltolate-treated aged rabbit as Alzheimer’s animal model. Brain Res Rev. 52, 275–292 (2006).
24. Wu, D. C. et al. Protection against ischemic injury in primary cultured mouse astrocytes by bis(7)-tacrine, a novel acetylcholinesterase inhibitor [corrected]. Neurosci Lett. 288, 95–98 (2000).
25. Mohri, I., Eguchi, N., Suzuki, K., Urade, Y. & Taniike, M. Hematopoietic prostaglandin D synthase is expressed in microglia in the developing postnatal mouse brain. Glia. 42, 263–274 (2003).
26. Blodorn, B. P. et al. Expression of the beta-trace protein in human pachymeninx as revealed by in situ hybridization and immunocytochemistry. J Neurosci Res. 57, 730–734 (1999).
27. Hoffmann, A., Bachner, D., Betat, N., Lauber, J. & Gross, G. Developmental expression of murine Beta-trace in embryos and adult animals suggests a function in maturation and maintenance of blood-tissue barriers. Dev Dyn. 207, 332–343 (1996).
28. Fukuhara, A. et al. Lipocalin-type prostaglandin D synthase protects against oxidative stress-induced neuronal cell death. Biochem J. 443, 75–84 (2012).
29. Taniguchi, H. et al. Early induction of neuronal lipocalin-type prostaglandin D synthase after hypoxic-ischemic injury in developing brains. Neurosci Lett. 420, 39–44 (2007).
30. Matsugi, T., Kageyama, M., Nishimura, K., Giles, H. & Shirasawa, E. Selective prostaglandin D2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats. Eur J Pharmacol. 275, 245–250 (1995).
31. Angeli, V. et al. Activation of the D prostaglandin receptor 1 regulates immune and skin allergic responses. J Immunol. 172, 3882–3889 (2004).
32. Toyomoto, M. et al. Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures. FEBS Letters. 562, 211–215 (2004).
33. Geltz, E., Arslan, S. O., Sayan, H. P. & Linar, E. Effect of rapid eye-movement sleep deprivation on rat hypothalamic prostaglandins. Prostaglandins Leukot Essent Fatty Acids. 73, 391–396 (2005).
34. Ahmad, A. S., Ahmad, M., Maruyama, T., Narumiya, S. & Dor, S. Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute excitotoxicity in young and old mice. Age (Dordr). 32, 271–282 (2010).
35. Hirata, M., Kakizuka, A., Aizawa, M., Usukubi, F. & Narumiya, S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci USA 91, 11192–11196 (1994).
36. Mita, A. N. & Breyer, R. M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 103, 147–166 (2004).
37. Saleem, S. et al. PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury. Eur J Neurosci. 26, 73–78 (2007).
38. Hirai, H. et al. Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol. 168, 981–985 (2002).
39. Liu, X. et al. U-shape suppressive effect of phenol red on the epileptiform burst activity via activation of estrogen receptors in primary hippocampal culture. PLoS One. 8, e60189 (2013).
40. Bertholf, R. L. et al. A long-term intravenous model of aluminum maltol toxicity in rabbits: tissue distribution, hepatic, renal, and neuronal cytoskeletal changes associated with systemic exposure. Toxicol Appl Pharmacol. 98, 58–74 (1989).
41. Chen, T. J., Hung, H. S., Wang, D. C. & Chen, S. S. The protective effect of Rho-associated kinase inhibitor on aluminum-induced neurotoxicity in rat cortical neurons. *Toxicol Sci.* **116**, 264–272 (2010).

42. Lobner, D. Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis? *J Neurosci Methods* **96**, 147–152 (2000).

**Acknowledgements**

This reported study was supported by research grants from the Natural Science Foundation of China (No. 81070972 and No. 30672211).

**Author Contributions**

J.Y. made substantial contribution to conception and design and performance of the study. Q.Y., Y.W., Y.Y., C.J., X.H., S.M., S.K., X.T., Y.L. and G.L. participated in performance of all *in vivo* experiments and carried out the data analysis. J.M. participated in performance of the study and in writing the manuscript. All authors read and approved the final manuscript.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Ma, J. *et al.* Effect of the PGD2-DP signaling pathway on primary cultured rat hippocampal neuron injury caused by aluminum overload. *Sci. Rep.* **6**, 24646; doi: 10.1038/srep24646 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/